Tag: mortality

Peer-Reviewed Study in Nature Scientific Reports Demonstrates Non-Invasive Fat Reduction Using Alma’s Energy-Based Technology

CAESAREA, Israel, June 27, 2025 /PRNewswire/ -- A newly published, peer-reviewed study in Nature Scientific Reports, part of the prestigious Nature Portfolio, presents compelling clinical...

Peer-Reviewed Study in Nature Scientific Reports Demonstrates Non-Invasive Fat Reduction Using Alma’s Energy-Based Technology

CAESAREA, Israel, June 27, 2025 /PRNewswire/ -- A newly published, peer-reviewed study in Nature Scientific Reports, part of the prestigious Nature Portfolio, presents compelling clinical...

Press release: Transparency Notification from Shareholders

Transparency Notification from Shareholders

Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives “Oscar of Italian Dermatology”

Dr. Roberta Lotti honoured for a pioneering work on PC111, reinforcing Scinai's strategic option agreement to acquire the Italian biotech company Pincell srl. JERUSALEM, June 26,...

Canada Life Reinsurance strengthens focus on structured reinsurance; ceases new business for U.S. traditional mortality risk reinsurance

BLUE BELL, Pa., June 25, 2025 /PRNewswire/ - Today, Canada Life Reinsurance, a wholly owned subsidiary of Great-West Lifeco Inc. (TSX: GWO) ("Lifeco") announced...

Grand Challenges Canada to Anchor Gavi’s Innovation Fund to Scale Immunization Solutions

New strategic partnership will accelerate the scale-up of high-impact immunization delivery innovations BRUSSELS, June 25, 2025 /CNW/ - Grand Challenges Canada (GCC), one of the world's...

Zynex Announces Award of UK Patent for Non-Invasive Detection of Sepsis

ENGLEWOOD, Colo., June 25, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices...

Nipocalimab showed greater sustained disease control versus approved FcRn blockers for generalised myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG

DARZALEX® (daratumumab) reçoit le premier avis favorable du CHMP pour les patients atteints d’un myélome multiple indolent à haut risque

En cas d’autorisation, le daratumumab deviendra la première option thérapeutique autorisée pour les patients atteints d’un myélome multiple indolent et présentant un risque élevé de développer un myélome multiple, offrant le potentiel de blocage de la progression de la maladie¹

Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia

Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disease1 with an estimated global incidence of approximately 1 in 14,000–18,000 live births2A phase II...

Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia

Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disease1 with an estimated global incidence of approximately 1 in 14,000–18,000 live births2A phase II...

Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and...

Bagsværd, Denmark, 23 June 2025 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Ozempic^® (once-weekly semaglutide) label to reflect the positive data from the STRIDE peripheral artery disease (PAD) functional outcomes trial.

PRIORITIZE PROSTATE SCREENING–IT’S THE BEST DEFENSE AGAINST PROSTATE CANCER, SAYS PROCURE

SOMERSET, N.J., June 23, 2025 /PRNewswire/ -- ProCure Proton Therapy Center reminds area residents about the critical importance to men of prostate-specific antigen (PSA)...

Nipocalimab showed greater sustained disease control versus approved FcRn blockers for generalised myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG

$100 No Deposit Bonus 200 Free Spins Real Money Casinos – All iGaming Experts Report Rising Demand for Free Spins Casinos

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with...

Peer-Reviewed Study in Nature Scientific Reports Demonstrates Non-Invasive Fat Reduction Using Alma’s Energy-Based Technology

Peer-Reviewed Study in Nature Scientific Reports Demonstrates Non-Invasive Fat Reduction Using Alma’s Energy-Based Technology

Press release: Transparency Notification from Shareholders

Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives “Oscar of Italian Dermatology”

Canada Life Reinsurance strengthens focus on structured reinsurance; ceases new business for U.S. traditional mortality risk reinsurance

Grand Challenges Canada to Anchor Gavi’s Innovation Fund to Scale Immunization Solutions

Zynex Announces Award of UK Patent for Non-Invasive Detection of Sepsis

Nipocalimab showed greater sustained disease control versus approved FcRn blockers for generalised myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published...

DARZALEX® (daratumumab) reçoit le premier avis favorable du CHMP pour les patients atteints d’un myélome multiple indolent à haut risque

Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia

Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia

Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and...

PRIORITIZE PROSTATE SCREENING–IT’S THE BEST DEFENSE AGAINST PROSTATE CANCER, SAYS PROCURE

Nipocalimab showed greater sustained disease control versus approved FcRn blockers for generalised myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published...

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us